Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€25.00

€25.00

-5.300%
-
-5.300%
-
 
02.05.24 / Tradegate WKN: A3CUMB / Name: Stevanato Group S.p.a. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Stevanato Group S.p.a. Stock

Stevanato Group S.p.a. took a tumble today and lost €0.000 (-5.300%).

Pros and Cons of Stevanato Group S.p.a. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Stevanato Group to Present at the Bank of America Securities Healthcare Conference: https://mms.businesswire.com/media/20220601006234/en/1474001/5/JPG_Logo_SG_RGB.jpg
Stevanato Group to Present at the Bank of America Securities Healthcare Conference


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries

Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024: https://mms.businesswire.com/media/20220601006234/en/1474001/5/JPG_Logo_SG_RGB.jpg
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries

Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares: https://mms.businesswire.com/media/20220601006234/en/1474001/5/JPG_Logo_SG_RGB.jpg
Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares


Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology